Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Receivables: 2020-2023

Historic Receivables for Kymera Therapeutics (KYMR) over the last 2 years, with Dec 2023 value amounting to $18.8 million.

  • Kymera Therapeutics' Receivables was N/A to $40.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $62.0 million, marking a year-over-year change of. This contributed to the annual value of $18.8 million for FY2023, which is N/A change from last year.
  • According to the latest figures from FY2023, Kymera Therapeutics' Receivables is $18.8 million, which was up 1,191.21% from $1.5 million recorded in FY2020.
  • Kymera Therapeutics' Receivables' 5-year high stood at $18.8 million during FY2023, with a 5-year trough of $1.5 million in FY2020.
  • In the last 1 years, Kymera Therapeutics' Receivables had a median value of $18.8 million in 2023 and averaged $18.8 million.